Skip to main content
Premium Trial:

Request an Annual Quote

DiNuzzo Takes Over as CEO of Strategic Diagnostics, Terry to Advise GeneNews, Lapidus Joins T2 Board, and More

NEW YORK (GenomeWeb News) - Strategic Diagnostics has appointed Francis DiNuzzo to serve as president and CEO, and to sit on the company’s board of directors. He was named interim CEO earlier this year.
DiNuzzo formerly was executive VP and chief commercial officer, positions he took on in February 2008. He spent 26 years in the life and analytical sciences industries, and he has served as VP and GM of chemical solutions, consumables and services, and integrated biology solutions at Agilent Technologies.

GeneNews has named Patrick Terry to be lead advisor for the US commercial launch of its biomarker test for determining risk of colorectal cancer. Terry is a co-founder of Genomic Health, and he also was director of consumer advocacy and government affairs at the firm. He is a co-founder and former president of the International Genetic Alliance.

CombiMatrix has named Fred Hutchinson Cancer Research Center scientist Muneesh Tewari to its scientific advisory board. Tewari, who is a researcher in The Hutch’s human biology division, has worked at Dana-Farber Cancer Institute, as a physician at Massachusetts General Hospital, and at Brigham and Women’s Hospital at Harvard Medical School.

BioNanomatrix has tapped Pui-Yan Kwok to serve on its scientific advisory board. Kwok, a professor at the University of California, San Francisco, studies whole-genome analysis and how to apply it to gene mapping and haplotyping. He has invented fluorescence-based SNP genotyping methods and he has been a member of the International HapMap Consortium Steering Committee.

Mark Sutherland will join GenVault as its senior VP of business development. In the job, Sutherland will be responsible for partnering, licensing, and strategic alliances. Sutherland previously was VP of strategic alliances at GE Healthcare, and before that he was a VP in the same area at Amersham Biosciences.

TheraGenetics this week named the four inaugural members of its scientific advisory board. These SAB members include Shitij Kapur, who is vice dean and professor at the Institute of Psychiatry at King's College London and who will chair the SAB; Peter Jones, a professor and department head of psychiatry at the University of Cambridge; Anil Malhotra, director of psychiatry research at the Zucker Hillside Hospital at the North Shore-Long Island Jewish Health System and associate professor of psychiatry at the Albert Einstein College of Medicine; and Pak Sham, who is chair professor and department head of psychiatry at the University of Hong Kong.

Stan Lapidus has joined the board of directors of privately held diagnostics firm T2 Biosystems. Lapidus recently served as CEO of Helicos BioSciences, where he still holds the position of chairman, and he was a founder of Cytyc and Exact Sciences.

Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in PEOPLE, a weekly roundup of industry comings and goings.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.